CONCURRENT DOSING WITH OMALIZUMAB MITIGATES ANAPHYLAXIS DURING ULTRA-RUSH HONEY BEE VENOM IMMUNOTHERAPY IN MONOCLONAL MAST CELL ACTIVATION SYNDROME

被引：0
|
作者：
da Silva, Elizabeth [1 ,2 ]
Choe, Renee [1 ]
Field, Elise [1 ]
Wilson, Anastasia [1 ]
Randall, Katrina [1 ,2 ]
机构：
[1] Canberra Hosp, Dept Immunol, Canberra, ACT, Australia
[2] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia
来源：
INTERNAL MEDICINE JOURNAL | 2012年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：17 / 17
页数：1
相关论文
共 10 条
  • [1] Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome
    da Silva, Elizabeth Nicole
    Randall, Katrina Louise
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2013, 1 (06): : 687 - 688
  • [2] Pre-treatment with omalizumab allows ultra-rush honey bee venom immunotherapy in patients with mast cell disease
    da Silva, E. N.
    Randall, K. L.
    ALLERGY, 2014, 69 : 398 - 399
  • [3] Omalizumab For a Case Of Monoclonal Mast Cell Activation Syndrome With Recurrent Anaphylaxis
    Jagdis, Amanda
    Vadas, Peter
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB27 - AB27
  • [4] Successful treatment of refractory anaphylaxis using omalizumab in monoclonal mast cell activation syndrome
    O'Keefe, A.
    ALLERGY, 2018, 73 : 466 - 466
  • [5] Ultra-rush venom immunotherapy induces differential T cell activation and regulatory patterns according to the severity of allergy
    Mamessier, E.
    Birnbaum, J.
    Dupuy, P.
    Vervloet, D.
    Magnan, A.
    CLINICAL AND EXPERIMENTAL ALLERGY, 2006, 36 (06): : 704 - 713
  • [6] Omalizumab effectively prevents recurrent refractory anaphylaxis in patient with monoclonal mast cell activation syndrome
    Jagdis, Amanda
    Vadas, Peter
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2014, 113 (01) : 115 - 116
  • [7] Idiopathic mast cell activation disorder: control of idiopathic and venom immunotherapy associated anaphylaxis with low dose Omalizumab
    Berry, R.
    Hollingsworth, P.
    Lucas, M.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 1209 - 1209
  • [8] Laboratory markers of mast cell and basophil activation in monitoring rush immunotherapy in bee venom-allergic children
    Cichocka-Jarosz, Ewa
    Dorynska, Agnieszka
    Pietrzyk, Jacek J.
    Spiewak, Radoslaw
    IMMUNOTHERAPY, 2011, 3 (08) : 1013 - 1017
  • [9] Bee venom allergy immunotherapy/omalizumabIdiopathic non-clonal mast cell activation syndrome, pre-syncopal symptoms and bradycardia: case report
    Reactions Weekly, 2020, 1785 (1) : 107 - 107
  • [10] Fatal anaphylaxis following a hornet sting in a yellow jacket venom-sensitized patient with undetected monoclonal mast cell activation syndrome and without previous history of a systemic sting reaction
    Blank, Simon
    Pehlivanli, Sinan
    Methe, Heiko
    Schmidt-Weber, Carsten B.
    Biedermann, Tilo
    Horny, Hans-Peter
    Kristensen, Thomas
    Amar, Yacine
    Koeberle, Martin
    Brockow, Knut
    Stoemmer, Peter E.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2020, 8 (01): : 401 - +
1